Bristol Myers Squibb (BMY) Common Equity (2009 - 2026)

Bristol Myers Squibb (BMY) has reported Common Equity for 18 consecutive years, with $22.3 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Common Equity rose 27.62% year-over-year to $22.3 billion in Q2 2026; TTM through Jun 2026 was $22.3 billion, a 27.62% increase from a year earlier, with the FY2025 full-year figure at $18.5 billion, up 12.92% from the prior year.
• Common Equity was $22.3 billion for Q2 2026 at Bristol Myers Squibb, up from $20.1 billion in the prior quarter.
• Over five years, Common Equity peaked at $32.7 billion in Q3 2022 and troughed at $16.4 billion in Q4 2024.
• A 5-year average of $24.0 billion and a median of $21.2 billion in 2026 frame the typical range for Common Equity.
• Across the five-year window, Common Equity slumped 48.1% in 2024 and advanced 27.62% in 2026, its largest moves.
• Over 5 years, Common Equity stood at $31.1 billion in 2022, then retreated by 5.25% to $29.5 billion in 2023, then tumbled by 44.42% to $16.4 billion in 2024, then gained by 12.92% to $18.5 billion in 2025, then rose by 20.6% to $22.3 billion in 2026.
• The last three Common Equity figures came in at $22.3 billion (Q2 2026), $20.1 billion (Q1 2026), and $18.5 billion (Q4 2025), per Business Quant data.